Hunter Syndrome Treatment Market
Hunter Syndrome Treatment Market Forecasts to 2030 - Global Analysis By Treatment Type (Enzyme Replacement Therapy (ERT), Hematopoietic Stem Cell Transplant (HSCT), Gene Therapy and Other Treatment Types), Complication Type, Route of Administration, Severity, End User and By Geography
According to Stratistics MRC, the Global Hunter Syndrome Treatment Market is accounted for $1.3 billion in 2024 and is expected to reach $1.9 billion by 2030 growing at a CAGR of 7.3% during the forecast period. Hunter Syndrome, a rare genetic disorder caused by a deficiency of the enzyme iduronate-2-sulfatase, leads to progressive health issues. Treatment primarily focuses on managing symptoms and improving quality of life. Enzyme replacement therapy (ERT) is the most common approach, providing patients with the missing enzyme to reduce substrate accumulation. Additional treatments may include physical therapy to maintain mobility, respiratory care to address breathing difficulties, and surgical interventions for orthopedic issues or organ function support.
According to the Genetic and Rare Diseases Information Center (GARD), there can be an estimated 7,000 rare diseases and the total number of individuals in the U.S. from these rare diseases can be 25-30 million.
Market Dynamics:
Driver:
Growing awareness of hunter syndrome
Growing awareness of Hunter Syndrome is reshaping the treatment market by promoting earlier diagnoses and a deeper understanding of the condition. Increased education among healthcare professionals and advocacy groups has spurred demand for innovative therapies, such as enzyme replacement therapy (ERT). This awareness fosters collaboration among stakeholders, enhancing patient support and outcomes, ultimately expanding treatment options and improving the overall landscape for those affected by the disorder.
Restraint:
Lack of skilled professionals
The lack of skilled professionals in the market poses significant challenges, leading to delayed diagnoses and suboptimal care for patients. Insufficient expertise can hinder effective implementation of innovative therapies, such as enzyme replacement and gene therapies. This shortage limits access to specialized treatment, reducing patient support and overall quality of care. Consequently, it exacerbates health disparities and diminishes the potential for improved outcomes in individuals affected by the disorder.
Opportunity:
Increased healthcare expenditure
Increased healthcare expenditure in the market reflects the rising demand for advanced therapies and comprehensive care. As awareness grows, investments in enzyme replacement therapy (ERT) and gene therapies expand, driving up costs associated with research, development, and patient management. This surge in spending aims to improve treatment accessibility and outcomes but may strain healthcare budgets. Ultimately, it highlights the need for sustainable funding and innovative approaches to support affected individuals effectively.
Threat:
Limited awareness in emerging markets
Limited awareness of Hunter Syndrome in emerging markets significantly hinders the treatment landscape, resulting in delayed diagnoses and inadequate access to care. Many healthcare providers may lack knowledge about the disorder, leading to misdiagnosis or underdiagnosis. This gap restricts the availability of innovative therapies ultimately impacting patient outcomes. Increased education and advocacy are essential to improve awareness and support for affected individuals in these regions.
Covid-19 Impact:
The COVID-19 pandemic adversely impacted the market by disrupting healthcare services and limiting access to essential therapies. Routine medical visits were postponed, delaying diagnoses and treatment initiation for many patients. Additionally, supply chain disruptions affected the availability of enzyme replacement therapies. The focus on pandemic response shifted resources away from rare diseases, highlighting the need for resilient healthcare systems that prioritize continuity of care for patients with rare conditions like Hunter Syndrome.
The musculoskeletal segment is projected to be the largest during the forecast period
The musculoskeletal segment is projected to account for the largest market share during the projection period. Patients may require interventions such as physical therapy, orthopedic surgeries, and pain management strategies to address these complications. The growing understanding of musculoskeletal manifestations drives demand for specialized treatments and multidisciplinary care approaches. Effective management is crucial to improving patients' quality of life and overall functional outcomes.
The diagnostic centers segment is expected to have the highest CAGR during the forecast period
The diagnostic centers segment is expected to have the highest CAGR during the extrapolated period. Advanced testing methods, including genetic testing and enzyme assays, are essential for confirming the disorder. Increased collaboration between diagnostic centers and healthcare providers enhances awareness and promotes timely intervention. As more centers specialize in rare genetic disorders, they contribute to improved patient outcomes and better access to targeted therapies, ultimately advancing care for those affected.
Region with largest share:
North America region is projected to account for the largest market share during the forecast period. Enzyme replacement therapy (ERT) has gained traction, supported by ongoing clinical research and patient advocacy efforts. Access to specialized care and diagnostic services is improving, although challenges remain in terms of cost and insurance coverage. The collaboration among healthcare providers, pharmaceutical companies, and advocacy groups is crucial for enhancing patient outcomes in the region.
Region with highest CAGR:
Asia Pacific is expected to register the highest growth rate over the forecast period due to increasing prevalence of genetic disorders. The market is characterized by diverse treatment modalities, including ERT, stem cell transplants, and surgical interventions, with ERT currently dominating due to its efficacy in managing symptoms like joint mobility and facial coarseness. Countries such as Japan and China are leading the charge, benefiting from early diagnosis and increased awareness of rare diseases.
Key players in the market
Some of the key players in Hunter Syndrome Treatment market include Takeda Pharmaceutical Company Limited, Medtronic, CANbridge Life Sciences Ltd., Novartis AG, Zimmer Biomet, Sangamo Therapeutics, F. Hoffmann-La Roche Ltd, Jasper Therapeutics, Inc., GSK Plc., Denali Therapeutics, Abbott, JCR Pharmaceuticals Co., Ltd. , Bayer AG, Johnson & Johnson Services, Inc. and Stryker Corporation.
Key Developments:
In September 2024, Denali Therapeutics announced plans to seek accelerated FDA approval for its investigational treatment, DNL310, to address Hunter syndrome (MPS II). Following productive discussions with the FDA, the company is set to submit a Biologics License Application (BLA) by early 2025.
In January 2024, Clinigen Group plc announced that it had received manufacturing and marketing approval for Hunterase (Disulfate-beta) ICV 15mg, under its strategic alliance with GC Pharma in Japan. This approval may help the company to acquire an enhanced customer base.
Treatment Types Covered:
• Enzyme Replacement Therapy (ERT)
• Hematopoietic Stem Cell Transplant (HSCT)
• Gene Therapy
• Other Treatment Types
Complication Types Covered:
• Cardiovascular
• Respiratory
• Musculoskeletal
• Neurological
• Ocular
• Hepatic
• Renal
• Hematological
• Other Complication Types
Route of Administration Covered:
• Intravenous (IV)
• Intracerebroventricular (ICV)
Severity Covered:
• Mild
• Moderate
• Severe
End Users Covered:
• Hospitals
• Diagnostic Centers
• Specialty Clinics
• Homecare Settings
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Hunter Syndrome Treatment Market, By Treatment Type
5.1 Introduction
5.2 Enzyme Replacement Therapy (ERT)
5.3 Hematopoietic Stem Cell Transplant (HSCT)
5.4 Gene Therapy
5.5 Other Treatment Types
6 Global Hunter Syndrome Treatment Market, By Complication Type
6.1 Introduction
6.2 Cardiovascular
6.3 Respiratory
6.4 Musculoskeletal
6.5 Neurological
6.6 Ocular
6.7 Hepatic
6.8 Renal
6.9 Hematological
6.10 Other Complication Types
7 Global Hunter Syndrome Treatment Market, By Route of Administration
7.1 Introduction
7.2 Intravenous (IV)
7.3 Intracerebroventricular (ICV)
8 Global Hunter Syndrome Treatment Market, By Severity
8.1 Introduction
8.2 Mild
8.3 Moderate
8.4 Severe
9 Global Hunter Syndrome Treatment Market, By End User
9.1 Introduction
9.2 Hospitals
9.3 Diagnostic Centers
9.4 Specialty Clinics
9.5 Homecare Settings
9.6 Other End Users
10 Global Hunter Syndrome Treatment Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 Takeda Pharmaceutical Company Limited
12.2 Medtronic
12.3 CANbridge Life Sciences Ltd.
12.4 Novartis AG
12.5 Zimmer Biomet
12.6 Sangamo Therapeutics
12.7 F. Hoffmann-La Roche Ltd
12.8 Jasper Therapeutics, Inc.
12.9 GSK Plc.
12.10 Denali Therapeutics
12.11 Abbott
12.12 JCR Pharmaceuticals Co., Ltd.
12.13 Bayer AG
12.14 Johnson & Johnson Services, Inc.
12.15 Stryker Corporation
List of Tables
1 Global Hunter Syndrome Treatment Market Outlook, By Region (2022-2030) ($MN)
2 Global Hunter Syndrome Treatment Market Outlook, By Treatment Type (2022-2030) ($MN)
3 Global Hunter Syndrome Treatment Market Outlook, By Enzyme Replacement Therapy (ERT) (2022-2030) ($MN)
4 Global Hunter Syndrome Treatment Market Outlook, By Hematopoietic Stem Cell Transplant (HSCT) (2022-2030) ($MN)
5 Global Hunter Syndrome Treatment Market Outlook, By Gene Therapy (2022-2030) ($MN)
6 Global Hunter Syndrome Treatment Market Outlook, By Other Treatment Types (2022-2030) ($MN)
7 Global Hunter Syndrome Treatment Market Outlook, By Complication Type (2022-2030) ($MN)
8 Global Hunter Syndrome Treatment Market Outlook, By Cardiovascular (2022-2030) ($MN)
9 Global Hunter Syndrome Treatment Market Outlook, By Respiratory (2022-2030) ($MN)
10 Global Hunter Syndrome Treatment Market Outlook, By Musculoskeletal (2022-2030) ($MN)
11 Global Hunter Syndrome Treatment Market Outlook, By Neurological (2022-2030) ($MN)
12 Global Hunter Syndrome Treatment Market Outlook, By Ocular (2022-2030) ($MN)
13 Global Hunter Syndrome Treatment Market Outlook, By Hepatic (2022-2030) ($MN)
14 Global Hunter Syndrome Treatment Market Outlook, By Renal (2022-2030) ($MN)
15 Global Hunter Syndrome Treatment Market Outlook, By Hematological (2022-2030) ($MN)
16 Global Hunter Syndrome Treatment Market Outlook, By Other Complication Types (2022-2030) ($MN)
17 Global Hunter Syndrome Treatment Market Outlook, By Route of Administration (2022-2030) ($MN)
18 Global Hunter Syndrome Treatment Market Outlook, By Intravenous (IV) (2022-2030) ($MN)
19 Global Hunter Syndrome Treatment Market Outlook, By Intracerebroventricular (ICV) (2022-2030) ($MN)
20 Global Hunter Syndrome Treatment Market Outlook, By Severity (2022-2030) ($MN)
21 Global Hunter Syndrome Treatment Market Outlook, By Mild (2022-2030) ($MN)
22 Global Hunter Syndrome Treatment Market Outlook, By Moderate (2022-2030) ($MN)
23 Global Hunter Syndrome Treatment Market Outlook, By Severe (2022-2030) ($MN)
24 Global Hunter Syndrome Treatment Market Outlook, By End User (2022-2030) ($MN)
25 Global Hunter Syndrome Treatment Market Outlook, By Hospitals (2022-2030) ($MN)
26 Global Hunter Syndrome Treatment Market Outlook, By Diagnostic Centers (2022-2030) ($MN)
27 Global Hunter Syndrome Treatment Market Outlook, By Specialty Clinics (2022-2030) ($MN)
28 Global Hunter Syndrome Treatment Market Outlook, By Homecare Settings (2022-2030) ($MN)
29 Global Hunter Syndrome Treatment Market Outlook, By Other End Users (2022-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
